LOINC_NUM
stringlengths 3
8
| COMPONENT
stringlengths 2
246
| PROPERTY
stringlengths 1
29
| TIME_ASPCT
stringlengths 1
15
| SYSTEM
stringlengths 1
106
| SCALE_TYP
stringclasses 10
values | METHOD_TYP
stringlengths 1
57
⌀ | CLASS
stringlengths 2
24
| CLASSTYPE
int64 1
4
| LONG_COMMON_NAME
stringlengths 3
254
| SHORTNAME
stringlengths 2
51
⌀ | EXTERNAL_COPYRIGHT_NOTICE
stringlengths 39
2.6k
⌀ | STATUS
stringclasses 4
values | VersionFirstReleased
stringlengths 1
7
| VersionLastChanged
stringlengths 1
5
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9344-3 | Coproporphyrin 1/Coproporphyrin.total | MRto | 24H | Urine | Qn | null | CHEM | 1 | Coproporphyrin 1/Coproporphyrin.total [Mass Ratio] in 24 hour Urine | Copro1/Copro total 24h Ur | null | ACTIVE | 1.0i | 2.7 |
93443-0 | Self-care abilities | Find | Pt | ^Patient | Nom | null | CLIN | 2 | Self-care abilities | Self-care abilities | null | ACTIVE | 2.67 | 2.67 |
93444-8 | Accessibility of home entrance | Find | Pt | ^Patient | Nom | null | CLIN | 2 | Accessibility of home entrance | Access of home entrance | null | ACTIVE | 2.67 | 2.67 |
93445-5 | Accessibility note | Find | Pt | Patient's home | Doc | Nurse | DOC.MISC | 2 | Accessibility note Patient's home Nurse | Accessibility note Pt's home Nurse | null | ACTIVE | 2.67 | 2.67 |
93446-3 | Accessibility of home interior | Find | Pt | ^Patient | Nom | null | CLIN | 2 | Accessibility of home interior | Access home int | null | ACTIVE | 2.67 | 2.67 |
93447-1 | Home accessibility modification responsible party | Find | Pt | ^Patient | Nom | null | CLIN | 2 | Home accessibility modification responsible party | Home access mod responsible party | null | ACTIVE | 2.67 | 2.67 |
93448-9 | Home accessibility evaluation status | Find | Pt | ^Patient | Nom | null | DOC.MISC | 2 | Home accessibility evaluation status | Home access eval status | null | ACTIVE | 2.67 | 2.67 |
93449-7 | Appointment of legal guardian | Find | Pt | ^Patient | Nom | null | ADMIN.PATIENT | 2 | Appointment of legal guardian | Appt legal guardian | null | ACTIVE | 2.67 | 2.67 |
9345-0 | Coproporphyrin 3 | MCnc | Pt | Urine | Qn | null | CHEM | 1 | Coproporphyrin 3 [Mass/volume] in Urine | Copro3 Ur-mCnc | null | ACTIVE | 1.0i | 2.73 |
93450-5 | Coagulation factor VIII Inhibitor | ACnc | Pt | PPP | Qn | Chromo | COAG | 1 | Coagulation factor VIII inhibitor [Units/volume] in Platelet poor plasma by Chromogenic method | Fact VIII Inhib PPP Chro-aCnc | null | ACTIVE | 2.67 | 2.67 |
93451-3 | Nor-W-18+Nor-W-15 | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | Nor-W-18+Nor-W-15 [Mass/volume] in Urine by Confirmatory method | Nor-W-18+Nor-W-15 Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93452-1 | W-19 | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | W-19 [Mass/volume] in Urine by Confirmatory method | W-19 Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93453-9 | W-15 | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | W-15 [Mass/volume] in Urine by Confirmatory method | W-15 Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93454-7 | W-18 | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | W-18 [Mass/volume] in Urine by Confirmatory method | W-18 Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93455-4 | IC-26 | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | IC-26 [Mass/volume] in Urine by Confirmatory method | IC-26 Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93456-2 | MT-45 | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | MT-45 [Mass/volume] in Urine by Confirmatory method | MT-45 Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93457-0 | AH-8529 | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | AH-8529 [Mass/volume] in Urine by Confirmatory method | AH-8529 Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93458-8 | AH-8533 | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | AH-8533 [Mass/volume] in Urine by Confirmatory method | AH-8533 Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93459-6 | U-47700 | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | U-47700 [Mass/volume] in Urine by Confirmatory method | U-47700 Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93460-4 | AH-7921 | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | AH-7921 [Mass/volume] in Urine by Confirmatory method | AH-7921 Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93461-2 | 4-Methoxybutyrylfentanyl | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | 4-Methoxybutyrylfentanyl [Mass/volume] in Urine by Confirmatory method | 4-Methbutfentanyl Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93462-0 | Norcarfentanil | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | Norcarfentanil [Mass/volume] in Urine by Confirmatory method | Norcarfentanil Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93463-8 | Ocfentanil | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | Ocfentanil [Mass/volume] in Urine by Confirmatory method | Ocfentanil Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93464-6 | 4-Fluorofentanyl | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | p-Fluorofentanyl [Mass/volume] in Urine by Confirmatory method | 4-Fluorofentanyl Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93465-3 | 3-Methylfentanyl | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | 3-Methylfentanyl [Mass/volume] in Urine by Confirmatory method | 3-Me-fentanyl Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93466-1 | Valerylfentanyl | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | Valerylfentanyl [Mass/volume] in Urine by Confirmatory method | Valerylfentanyl Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93467-9 | Butyrylfentanyl | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | Butyrylfentanyl [Mass/volume] in Urine by Confirmatory method | Butyrylfentanyl Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
9346-8 | Lipoprotein.beta | MCnc | Pt | Ser/Plas | Qn | Calculated | CHEM | 1 | Lipoprotein.beta [Mass/volume] in Serum or Plasma by calculation | LDL SerPl Calc-mCnc | null | ACTIVE | 1.0i | 2.73 |
93468-7 | Acrylfentanyl | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | Acrylfentanyl [Mass/volume] in Urine by Confirmatory method | Acrylfentanyl Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93469-5 | 4-Fluorobutyrylfentanyl | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | 4-Fluorobutyrylfentanyl [Mass/volume] in Urine by Confirmatory method | 4-Fluorobutyrylfentanyl Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93470-3 | Furanylfentanyl | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | Furanylfentanyl [Mass/volume] in Urine by Confirmatory method | Furanylfentanyl Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93471-1 | Acetyl norfentanyl | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | Acetyl norfentanyl [Mass/volume] in Urine by Confirmatory method | Acetyl norfentanyl Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93472-9 | 4-Methylphenethylacetylfentanyl | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | 4-Methylphenethylacetylfentanyl [Mass/volume] in Urine by Confirmatory method | 4-MetPhenEthAcetFentanyl Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93473-7 | Beta hydroxythiofentanyl | MCnc | Pt | Urine | Qn | Confirm | DRUG/TOX | 1 | Beta hydroxythiofentanyl [Mass/volume] in Urine by Confirmatory method | B-OH thiofentanyl Ur Cfm-mCnc | null | ACTIVE | 2.67 | 2.67 |
93474-5 | Synthetic opioids panel | - | Pt | Urine | - | Confirm | PANEL.DRUG/TOX | 1 | Synthetic opioids panel - Urine by Confirmatory method | Synthetic opioids pnl Ur Cfm | null | ACTIVE | 2.67 | 2.67 |
93475-2 | Busulfan clearance | VRatCnt | Stdy | Plas | Qn | null | DRUG/TOX | 1 | Busulfan clearance from plasma over study | Busulfan Cl from Plas | null | ACTIVE | 2.67 | 2.67 |
9347-6 | pH.combined acid | LsCnc | Pt | Gast fld | Qn | null | CHEM | 1 | pH combined acid of Gastric fluid | pH Combined Ac Gast | null | ACTIVE | 1.0i | 2.42 |
93476-0 | Busulfan | TmSCnc | Stdy | Plas | Qn | null | DRUG/TOX | 1 | Busulfan [Area under the curve] in Plasma | Busulfan Plas-AUC | null | ACTIVE | 2.67 | 2.67 |
93477-8 | Busulfan given | Mass | XXX | Dose | Qn | null | DRUGDOSE | 1 | Busulfan given [Mass] of Dose | Busulfan Gvn ?Tm Dose | null | ACTIVE | 2.67 | 2.68 |
93478-6 | Busulfan area under the curve panel | - | Stdy | Plas | Qn | null | PANEL.DRUG/TOX | 1 | Busulfan area under the curve panel - Plasma | Busulfan AUC Pnl Plas | null | ACTIVE | 2.67 | 2.67 |
93479-4 | Observation interpretation | Imp | Pt | XXX | Nom | null | MISC | 1 | Observation interpretation | Observation Imp | null | ACTIVE | 2.67 | 2.69 |
93480-2 | Cortisol post corticotropin releasing hormone stimulation panel | - | Pt | Ser/Plas | Qn | null | PANEL.CHAL | 1 | Cortisol post CRH stimulation panel - Serum or Plasma | Cortisol p CRH stimulation Pnl SerPl | null | ACTIVE | 2.67 | 2.67 |
93481-0 | Cortisol^10M post 1 ug/kg CRH IV | MCnc | Pt | Ser/Plas | Qn | null | CHAL | 1 | Cortisol [Mass/volume] in Serum or Plasma --10 minutes post 1 ug/kg CRH IV | Cortis 10M p 1 ug/kg CRH IV SerPl-mCnc | null | ACTIVE | 2.67 | 2.67 |
93482-8 | Cortisol^1M pre 1 ug/kg CRH IV | MCnc | Pt | Ser/Plas | Qn | null | CHAL | 1 | Cortisol [Mass/volume] in Serum or Plasma --1 minute pre 1 ug/kg CRH IV | Cortis 1M pre 1 ug/kg CRH IV SerPl-mCnc | null | ACTIVE | 2.67 | 2.67 |
93483-6 | Cortisol^2M post 1 ug/kg CRH IV | MCnc | Pt | Ser/Plas | Qn | null | CHAL | 1 | Cortisol [Mass/volume] in Serum or Plasma --2 minutes post 1 ug/kg CRH IV | Cortis 2M p 1 ug/kg CRH IV SerPl-mCnc | null | ACTIVE | 2.67 | 2.67 |
9348-4 | pH.free acid | LsCnc | Pt | Gast fld | Qn | null | CHEM | 1 | pH free acid of Gastric fluid | pH Free Ac Gast | null | ACTIVE | 1.0i | 2.73 |
93484-4 | Cortisol^5M pre 1 ug/kg CRH IV | MCnc | Pt | Ser/Plas | Qn | null | CHAL | 1 | Cortisol [Mass/volume] in Serum or Plasma --5 minutes pre 1 ug/kg CRH IV | Cortis 5M pre 1 ug/kg CRH IV SerPl-mCnc | null | ACTIVE | 2.67 | 2.67 |
93485-1 | Columbia - suicide severity rating scale - very young child or cognitively impaired - lifetime recent | - | Pt | ^Patient | - | C-SSRS | PANEL.SURVEY.CSSRS | 4 | Columbia - suicide severity rating scale - very young child or cognitively impaired - lifetime recent [C-SSRS] | null | © 2008 Research Foundation of Mental Hygiene, Inc. Used with permission | ACTIVE | 2.67 | 2.68 |
93486-9 | Has subject engaged in self-injurious behavior, intent unknown | Find | 3Mo | ^Patient | Ord | null | SURVEY.CSSRS | 4 | Has subject engaged in self-injurious behavior, intent unknown 3 months | null | null | ACTIVE | 2.67 | 2.67 |
93487-7 | Has subject engaged in self-injurious behavior, intent unknown | Find | Lifetime | ^Patient | Ord | null | SURVEY.CSSRS | 4 | Has subject engaged in self-injurious behavior, intent unknown Lifetime | null | null | ACTIVE | 2.67 | 2.67 |
93488-5 | Guanidinoacetate | SCnc | Pt | Bld.dot | Qn | null | CHEM | 1 | Guanidinoacetate [Moles/volume] in DBS | Guanidinoacetate DBS-sCnc | null | ACTIVE | 2.67 | 2.67 |
93489-3 | Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab.IgG | PrThr | Pt | Ser/Plas | Ord | CBA IFA | SERO | 1 | AMPAR2 IgG Ab [Presence] in Serum or Plasma by Cell binding immunofluorescent assay | AMPAR2 IgG SerPl Ql CBA IFA | null | ACTIVE | 2.67 | 2.69 |
93490-1 | Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab.IgG | Titr | Pt | Ser/Plas | Qn | IF | SERO | 1 | AMPAR2 IgG Ab [Titer] in Serum or Plasma by Immunofluorescence | AMPAR2 IgG Titr SerPl IF | null | ACTIVE | 2.67 | 2.67 |
93491-9 | Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab.IgG | PrThr | Pt | CSF | Ord | CBA IFA | SERO | 1 | AMPAR2 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay | AMPAR2 IgG CSF Ql CBA IFA | null | ACTIVE | 2.67 | 2.69 |
9349-2 | pH.total acid | LsCnc | Pt | Gast fld | Qn | null | CHEM | 1 | pH total acid of Gastric fluid | pH Total Ac Gast | null | ACTIVE | 1.0i | 2.42 |
93492-7 | Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab.IgG | Titr | Pt | CSF | Qn | IF | SERO | 1 | AMPAR2 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence | AMPAR2 IgG Titr CSF IF | null | ACTIVE | 2.67 | 2.67 |
93493-5 | 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Ab.IgG | ACnc | Pt | Ser | Qn | IA | CHEM | 1 | 3-Hydroxy-3-Methylglutaryl-coenzyme A reductase IgG Ab [Units/volume] in Serum by Immunoassay | HMGCR IgG Ser IA-aCnc | null | ACTIVE | 2.67 | 2.67 |
93494-3 | Buprenorphine | PrThr | Pt | Urine | Ord | Screen | DRUG/TOX | 1 | Buprenorphine [Presence] in Urine by Screen method | Buprenorphine Ur Ql Scn | null | ACTIVE | 2.67 | 2.67 |
93495-0 | 2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine | PrThr | Pt | Urine | Ord | Screen | DRUG/TOX | 1 | 2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Presence] in Urine by Screen method | EDDP Ur Ql Scn | null | ACTIVE | 2.67 | 2.67 |
93496-8 | Nortriptyline | PrThr | Pt | Urine | Ord | Screen | DRUG/TOX | 1 | Nortriptyline [Presence] in Urine by Screen method | Nortrip Ur Ql Scn | null | ACTIVE | 2.67 | 2.67 |
93497-6 | Moxifloxacin 3.0 ug/mL | Susc | Pt | Isolate | OrdQn | Method for Slow-growing mycobacteria | ABXBACT | 1 | Moxifloxacin 3 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria | Moxifloxacin 3 ug/mL Islt SlowMyco | null | ACTIVE | 2.67 | 2.67 |
93498-4 | Metabotropic glutamate receptor 1 Ab.IgG | PrThr | Pt | Ser | Ord | CBA IFA | SERO | 1 | Metabotropic glutamate receptor 1 IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay | mGluR1 IgG Ser Ql CBA IFA | null | ACTIVE | 2.67 | 2.69 |
93499-2 | Metabotropic glutamate receptor 1 Ab.IgG | Titr | Pt | Ser | Qn | IF | SERO | 1 | Metabotropic glutamate receptor 1 IgG Ab [Titer] in Serum by Immunofluorescence | mGluR1 IgG Titr Ser IF | null | ACTIVE | 2.67 | 2.67 |
93-5 | Cefodizime | Susc | Pt | Isolate | OrdQn | Agar diffusion | ABXBACT | 1 | Cefodizime [Susceptibility] by Disk diffusion (KB) | Cefodizime Islt KB | null | ACTIVE | 1.0 | 2.19 |
9350-0 | Sulfhydryls | PrThr | Pt | Urine | Ord | null | CHEM | 1 | Sulfhydryls [Presence] in Urine | Sulfhydryls Ur Ql | null | ACTIVE | 1.0i | 2.56 |
93500-7 | Metabotropic glutamate receptor 1 Ab.IgG | PrThr | Pt | CSF | Ord | CBA IFA | SERO | 1 | Metabotropic glutamate receptor 1 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay | mGluR1 IgG CSF Ql CBA IFA | null | ACTIVE | 2.67 | 2.69 |
93501-5 | Metabotropic glutamate receptor 1 Ab.IgG | Titr | Pt | CSF | Qn | IF | SERO | 1 | Metabotropic glutamate receptor 1 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence | mGluR1 IgG Titr CSF IF | null | ACTIVE | 2.67 | 2.67 |
93502-3 | N-methyl-D-aspartate receptor subunit 1 Ab.IgG | PrThr | Pt | CSF | Ord | CBA IFA | SERO | 1 | NMDAR subunit 1 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay | NMDAR1 IgG CSF Ql CBA IFA | null | ACTIVE | 2.67 | 2.69 |
93503-1 | N-methyl-D-aspartate receptor subunit 1 Ab.IgG | PrThr | Pt | Ser | Ord | CBA IFA | SERO | 1 | NMDAR subunit 1 IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay | NMDAR1 IgG Ser Ql CBA IFA | null | ACTIVE | 2.67 | 2.69 |
93504-9 | Cholesterol crystals | PrThr | Pt | Calculus | Ord | XR diffraction | CHEM | 1 | Cholesterol crystals [Presence] in Stone by X-ray diffraction | Cholest Cry Stone Ql XR diff | null | ACTIVE | 2.67 | 2.67 |
93505-6 | Heptacarboxylporphyrin I | SRat | 24H | Urine | Qn | null | CHEM | 1 | Heptacarboxylporphyrin I [Moles/time] in 24 hour Urine | Hepta-CP I 24h Ur-sRate | null | ACTIVE | 2.67 | 2.67 |
93506-4 | Heptacarboxylporphyrin III | SRat | 24H | Urine | Qn | null | CHEM | 1 | Heptacarboxylporphyrin III [Moles/time] in 24 hour Urine | Hepta-CP3 24h Ur-sRate | null | ACTIVE | 2.67 | 2.67 |
93507-2 | Hexacarboxylporphyrin I | SRat | 24H | Urine | Qn | null | CHEM | 1 | Hexacarboxylporphyrin I [Moles/time] in 24 hour Urine | Hexa-CP I 24h Ur-sRate | null | ACTIVE | 2.67 | 2.67 |
93508-0 | Hexacarboxylporphyrin III | SRat | 24H | Urine | Qn | null | CHEM | 1 | Hexacarboxylporphyrin III [Moles/time] in 24 hour Urine | Hexa-CPr3 24h Ur-sRate | null | ACTIVE | 2.67 | 2.67 |
93509-8 | Pentacarboxylporphyrin I | SRat | 24H | Urine | Qn | null | CHEM | 1 | Pentacarboxylporphyrin I [Moles/time] in 24 hour Urine | Penta-CPI 24h Ur-sRate | null | ACTIVE | 2.67 | 2.67 |
93510-6 | Pentacarboxylporphyrin III | SRat | 24H | Urine | Qn | null | CHEM | 1 | Pentacarboxylporphyrin III [Moles/time] in 24 hour Urine | Penta-CP3 24h Ur-sRate | null | ACTIVE | 2.67 | 2.67 |
93511-4 | Rickettsia rickettsii & Coxiella burnetii phase 1 & Coxiella burnetii phase 2 Ab.IgG panel | - | Pt | Ser | - | null | PANEL.MICRO | 1 | Rickettsia rickettsii and Coxiella burnetii phase 1 and Coxiella burnetii phase 2 IgG panel - Serum | R. rickettsii + C. burnetii 1 2 IgG Pnl | null | ACTIVE | 2.67 | 2.67 |
9351-8 | ALPRAZolam | PrThr | Pt | Urine | Ord | null | DRUG/TOX | 1 | ALPRAZolam [Presence] in Urine | Alpraz Ur Ql | null | ACTIVE | 1.0i | 2.73 |
9352-6 | Amphetamines | MCnt | Pt | Hair | Qn | null | DRUG/TOX | 1 | Amphetamines [Mass/mass] in Hair | Amphetamines Hair-mCnt | null | ACTIVE | 1.0i | 2.73 |
9353-4 | Baclofen | MCnc | Pt | Ser/Plas | Qn | null | DRUG/TOX | 1 | Baclofen [Mass/volume] in Serum or Plasma | Baclofen SerPl-mCnc | null | ACTIVE | 1.0i | 2.73 |
9354-2 | Benztropine | MCnc | Pt | Urine | Qn | null | DRUG/TOX | 1 | Benztropine [Mass/volume] in Urine | Benztropine Ur-mCnc | null | ACTIVE | 1.0i | 2.7 |
9355-9 | Bumetanide | MCnc | Pt | Ser/Plas | Qn | null | DRUG/TOX | 1 | Bumetanide [Mass/volume] in Serum or Plasma | Bumetanide SerPl-mCnc | null | ACTIVE | 1.0i | 2.7 |
9356-7 | busPIRone | MCnc | Pt | Ser/Plas | Qn | null | DRUG/TOX | 1 | busPIRone [Mass/volume] in Serum or Plasma | busPIRone SerPl-mCnc | null | ACTIVE | 1.0i | 2.73 |
935-7 | Blood product unit expiration | TmStp | Pt | ^BPU | Qn | null | BLDBK | 1 | Blood product unit expiration [Date and time] | BPU Expire Date BPU | null | ACTIVE | 1.0 | 2.73 |
9357-5 | Disulfiram | MCnc | Pt | Urine | Qn | null | DRUG/TOX | 1 | Disulfiram [Mass/volume] in Urine | Disulfiram Ur-mCnc | null | ACTIVE | 1.0i | 2.73 |
9358-3 | Lithium | MCnc | Pt | Saliva | Qn | null | DRUG/TOX | 1 | Lithium [Mass/volume] in Saliva (oral fluid) | Lithium Sal-mCnc | null | ACTIVE | 1.0i | 2.73 |
9359-1 | Tacrine | MCnc | Pt | Ser/Plas | Qn | null | DRUG/TOX | 1 | Tacrine [Mass/volume] in Serum or Plasma | Tacrine SerPl-mCnc | null | ACTIVE | 1.0i | 2.73 |
93598-1 | Intensity of ideation | - | Pt | ^Patient | - | C-SSRS.PCI | PANEL.SURVEY.CSSRS | 4 | Intensity of ideation [C-SSRS.PCI] | null | © 2008 Research Foundation of Mental Hygiene, Inc. Used with permission | ACTIVE | 2.67 | 2.67 |
93599-9 | Frequency of most severe suicidal ideation | Find | 1Mo | ^Patient | Ord | C-SSRS.PCI | SURVEY.CSSRS | 4 | Frequency of most severe suicidal ideation 1 month [C-SSRS.PCI] | null | © 2008 Research Foundation of Mental Hygiene, Inc. Used with permission | ACTIVE | 2.67 | 2.67 |
93600-5 | Frequency of most severe suicidal ideation | Find | Lifetime | ^Patient | Ord | C-SSRS.PCI | SURVEY.CSSRS | 4 | Frequency of most severe suicidal ideation Lifetime [C-SSRS.PCI] | null | © 2008 Research Foundation of Mental Hygiene, Inc. Used with permission | ACTIVE | 2.67 | 2.67 |
93603-9 | Multisection^WO & W contrast IV | Find | Pt | Head & Neck>Spine.cervical | Doc | CT | RAD | 2 | CT Head and Cervical spine WO and W contrast IV | CT Head+C-spine WO+W contr IV | null | ACTIVE | 2.67 | 2.67 |
93604-7 | Multisection | Find | Pt | Lower extremity.bilateral>Lower extremity arteries+Lower extremity veins | Doc | US.doppler | RAD | 2 | US.doppler Lower extremity arteries+veins - bilateral | DOP LE aa+vv-Bl | null | ACTIVE | 2.67 | 2.67 |
93605-4 | Views 2 or 3 | Find | Pt | Head>Skull & Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar & Pelvis>Sacrum+Coccyx | Doc | XR | RAD | 2 | XR Skull to Coccyx 2 or 3 Views | XR Skull to Coccyx 2V or 3V | null | ACTIVE | 2.67 | 2.67 |
93606-2 | Views 4 or 5 | Find | Pt | Head>Skull & Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar & Pelvis>Sacrum+Coccyx | Doc | XR | RAD | 2 | XR Skull to Coccyx 4 or 5 Views | XR Skull to Coccyx 4V or 5V | null | ACTIVE | 2.67 | 2.67 |
93607-0 | Views GE 6 | Find | Pt | Head>Skull & Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar & Pelvis>Sacrum+Coccyx | Doc | XR | RAD | 2 | XR Skull to Coccyx GE 6 Views | XR Skull to Coccyx GE 6V | null | ACTIVE | 2.67 | 2.67 |
93608-8 | Atrial contraction strain rate.max | ARat | Pt | Heart.ventricle.left | Qn | US.3D | CARD.US | 2 | Left ventricular Maximum atrial contraction strain rate by US 3D | LV Max atrial contract strain rate 3D US | null | ACTIVE | 2.67 | 2.67 |
9360-9 | Bartonella quintana Ab.IgG | Titr | Pt | Ser | Qn | null | MICRO | 1 | Bartonella quintana IgG Ab [Titer] in Serum | B quintana IgG Titr Ser | null | ACTIVE | 1.0i | 2.73 |
93609-6 | Atrial contraction strain rate.circumferential.max | LenRto | Pt | Heart.ventricle.left | Qn | US.3D | CARD.US | 2 | Left ventricular Maximum circumferential atrial contraction strain rate by US 3D | LV Max circ atrial contract st rt 3D US | null | ACTIVE | 2.67 | 2.67 |
93610-4 | Atrial contraction strain rate.longitudinal.max | ARat | Pt | Heart.ventricle.left | Qn | US.3D | CARD.US | 2 | Left ventricular Maximum longitudinal atrial contraction strain rate by US 3D | LV Max long atrial contract str rt 3D US | null | ACTIVE | 2.67 | 2.67 |
93611-2 | Circumferential strain rate.early diastole.max | ARat | Pt | Heart.ventricle.left | Qn | US.3D | CARD.US | 2 | Left ventricular Maximum circumferential strain rate during early diastole by US 3D | LV Max circ strain rate early dias 3D US | null | ACTIVE | 2.67 | 2.67 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.